Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
- Citado por SciELO
- Accesos
Links relacionados
- Citado por Google
- Similares en SciELO
- Similares en Google
Compartir
Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
Resumen
MARTINEZ-CARPIO, P.A.; BONAFONTE-MARQUEZ, E.; HEREDIA-GARCIA, C.D. y BONAFONTE-ROYO, S.. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review. Arch Soc Esp Oftalmol [online]. 2008, vol.83, n.10, pp.579-587. ISSN 0365-6691.
Purpose: Systematic review on efficacy and safety of intravitreal bevacizumab (IVB) in the treatment of neovascular glaucoma (NVG). All original papers published in Medline (prior to August 2008) were included. Methods: Search and selection of information on the internet and in Medline, validated by Kappa Index (K). Statistical and clinical study of the results in the selected articles on a one by one basis. Results: 26 original papers analyzed the efficacy and safety of the procedure in case reports and short series of cases (127 eyes). The efficacy calculated in the sample was 68.7% and the recurrence rate was 18.6% in 4.2 months of follow-up. All studies were after 2006 and none of them was a clinical randomized controlled assay. Ophthalmic complications were under 0.78% and no systemic complications were found. Conclusions: The use of bevacizumab demonstrates that intravitreal injections may be effective and useful to manipulate growth factors in the anterior chamber. IVB could serve as a first line treatment for NVG. Clinical trials are needed to confirm these results before its use is authorized.
Palabras clave : Bevacizumab; avastin; intravitreal injection; neovascular glaucoma; rubeosis iridis; laser photocoagulation; growth factors; systematic review.